Zelira Therapeutics (ZLDAF)
OTHER OTC:ZLDAF
ZLDAF Stock Chart & Stats
$0.21
-$0.03(-7.39%)
At close: 4:00 PM EST
$0.21
-$0.03(-7.39%)
Day’s Range― - ―
52-Week Range$0.20 - $0.48
Previous CloseN/A
Volume342.00
Average Volume (3M)189.00
Market Cap
$4.10M
Enterprise Value$8.08M
Total Cash (Recent Filing)$5.66K
Total Debt (Recent Filing)$2.14M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,897,155
10 Day Avg. Volume15
30 Day Avg. Volume189
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market Cap1.97
Enterprise Value/Revenue12.34K
Enterprise Value/Gross Profit-10.07
Enterprise Value/Ebitda-1.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Cannabinoid Therapeutics R&DA clear strategic focus on cannabinoid-based medicines gives Zelira durable domain expertise and a defined regulatory and commercial pathway. Specialisation supports long-term partnerships, targeted clinical development and differentiated product positioning in an expanding therapeutic niche.
Lean Operating StructureA very small headcount implies low fixed operating costs and greater runway per dollar of financing. For a research-heavy biotech, a lean structure enables disciplined cash deployment, flexibility to outsource trials or partner, and reduced dilution risk versus high-burn peers.
Signs Of Improving Free Cash FlowReported slight improvement in free cash flow growth signals management progress in reining in cash burn. Although still negative, a durable shift toward positive FCF would materially strengthen funding optionality and support continued development or strategic partnering.
Bears Say
Severe Revenue CollapseA near-total revenue decline severely weakens commercial viability and recurring cash inflows. Restoring sales levels will likely require months to years of consistent execution, new approvals or distribution deals, and imposes sustained pressure on funding and partner confidence.
Negative Shareholders' EquityNegative equity constrains financing options and increases reliance on dilutive raises or costly debt. This structural weakness can deter collaborators and suppliers, elevates refinancing risk, and typically requires substantial profitable operations or fresh capital to remediate over the medium term.
Persistent Negative Margins And Cash BurnSustained negative margins and operating cash flow erode reserves and limit capacity to fund trials or commercialisation. Without durable margin improvement or external capital, the company faces ongoing dilution risk and weakened ability to execute long-term development programs.
Zelira Therapeutics News
ZLDAF FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest stock price was $0.20 and its highest was $0.48 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Zelira Therapeutics’s market cap is $4.10M.
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Sep 02, 2026 which is in 156 days.
How were Zelira Therapeutics’s earnings last quarter?
Currently, no data Available
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,897,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in ZLDAF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zelira Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.75%
12-Months-Change
Fundamentals
Return on Equity
56.41%
Trailing 12-Months
Asset Growth
-75.38%
Trailing 12-Months
Company Description
Zelira Therapeutics
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
Technical Analysis
Invex Therapeutics Ltd.
―
Regeneus Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Neuroscientific Biopharmaceuticals Ltd.
―